International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation
Generics Players Could Benefit From Greater Control Over Their Prices In 2023
Executive Summary
Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.
You may also be interested in...
German Generic Reform To Relax Pediatric Pricing
Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.
Building The Pharma Supply Chain Of The Future
The worst of COVID-19’s disruption appears to be in the pharma supply chain’s rearview mirror, but logistics stakeholders still have a number of questions to answer and challenges to overcome as they attempt to become future-proof.
Commission Publications Highlight Urgency Of Rethinking Investment And Procurement Reform
Medicines for Europe has responded to two recent publications from the European Commission, calling for policy reforms to support the role of generic and biosimilar medicines.